Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Closes $600K Lifeline as Stock Tests 52-Week Lows Amid Dilution and Trial Rollout

By The Northwire Desk — AI Analysis Mar 30, 2026 · 06:03 ARCH · 0.55 Arch Biopartners Inc.
Executive Summary
  • Arch Biopartners closed a non-brokered private placement of 1,000,000 common shares at CAD $0.60 per share, generating gross proceeds of CAD $600,000.
  • The closing follows the March 30, 2026 announcement of the same terms, making this a purely administrative follow-through.
  • Proceeds are allocated to general working capital and operating expenses not covered by existing human-trial funding grants.
  • 81,667 shares were issued to a company officer as a related-party transaction, exempt from formal MI 61-101 valuation and minority approval thresholds.
  • All issued shares carry a standard four-month-plus-one-day statutory hold period.
  • Post-offering, the company reports 67,933,289 common shares outstanding.
Material Impact
  • The news is entirely expected and contains zero new fundamental or clinical information. The market had three days to price in the dilution and cash injection.
  • The raise size ($600,000) is immaterial relative to the capital requirements of running multiple Phase II trials across nine international sites. It provides only a short-term liquidity patch rather than a strategic runway extension.
  • Pricing at $0.60 represents a 42% discount to the November 2025 private placement price of $1.04, highlighting deteriorating market sentiment and a lack of external institutional demand.
  • The transaction does not alter the clinical development timeline, trial design, or fundamental risk profile of the LSALT peptide or PONTiAK programs.
ARCH · Price
Company Overview
  • Arch Biopartners is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute kidney injury (AKI) and chronic kidney disease (CKD).
  • Flagship Project: LSALT peptide, a first-in-class DPEP1 inhibitor targeting inflammation-mediated organ injury. It is currently in a Phase II, randomized, double-blind, placebo-controlled trial for cardiac surgery-associated AKI (CS-AKI).
  • Trial Design: Target enrollment of 240 patients across nine global sites. Primary endpoint is the percentage of subjects developing AKI within seven days post on-pump cardiac surgery per KDIGO criteria.
  • Secondary Pipeline: PONTiAK (cilastatin) in Phase II for toxin-induced AKI (698-patient target across Alberta sites, with U.S. expansion planned). Preclinical CKD platform targeting IL-32 acquired via Lipdro Therapeutics.
Read the original news release →

More from Arch Biopartners Inc.

Jun 04, 2026 · 07:41

Arch Biopartners Advances Dual AKI Pipeline Amid Steady Cash Burn and Dilutive Financing

Technical Study May 22, 2026 · 06:50

Arch Biopartners Doses First Patient in Phase II AKI Trial Amidst Dilution Concerns

Other Apr 30, 2026 · 07:00

Arch Biopartners Clinical Execution Continues Amidst Severe Capital Erosion and Liquidity Concerns

Other Apr 02, 2026 · 05:45

Arch Biopartners Closes Non-Brokered Private Placement

Financings Mar 24, 2026 · 09:13

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Production / Operations Mar 20, 2026 · 07:05

Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Other